DEA
GILD icon

DoubleLine ETF Adviser’s Gilead Sciences GILD Stock Holding History

DoubleLine ETF Adviser’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Sell
14,087
-1,513
-10% -$199K 0.73% 47
2026
Q1 		$2.17M Buy
+15,600
New +$2.18M 0.83% 38

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DoubleLine ETF Adviser's GILD Position: Q2 2026 in Review

DoubleLine ETF Adviser reduced its Gilead Sciences (GILD) stake by 9.7% in Q2 2026, selling an estimated $199K and leaving 14,087 shares worth $1.78M. The position accounts for 0.73% of the portfolio, ranked #47.

DoubleLine ETF Adviser first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.17M in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • DoubleLine ETF Adviser held 14,087 shares of Gilead Sciences worth $1.78M as of Q2 2026.
  • DoubleLine ETF Adviser sold 1,513 Gilead Sciences shares in Q2 2026, an estimated $199K.
  • Gilead Sciences made up 0.73% of DoubleLine ETF Adviser's portfolio in Q2 2026, its #47 holding.
  • DoubleLine ETF Adviser first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • DoubleLine ETF Adviser's Gilead Sciences position peaked at $2.17M in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.